Ongoing Studies

CONDOR (CRTH258d2301) A 96-week, two-arm, randomized, single-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation lase in patients with proliferative diabetic retinopathy. 

LIGHTSITE II (CSP003) A double masked, randomized, sham-controlled, parallel group, multi-center study to assess the safety and efficacy of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD)    

TALON-EXTENSION (CRTH258A2303E1) A 56-week, phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6 mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study

TOLERANT STUDY A phase IV randomised, controlled study investigating the efficacy and safety of aflibercept “Treat and Extend” using a strict retreatment regimen compared to a relaxed retreatment regimen in patients with exudative age-related macular degeneration (AMD)